文献速递其他结缔组织病

间充质干基质细胞通过PD-1/PD-L1信号轴改善系统性硬化症相关间质性肺病

Mesenchymal stromal cells ameliorate systemic sclerosis-interstitial lung disease via PD-1/PD-L1 signalling axis.
PubMed 文献 · RMD Open · 2026-01-06

研究分析30例系统性硬化症患者(含SSc-ILD与SSc-nILD亚组)及15例健康对照的T细胞PD-1表达,并在博来霉素诱导小鼠模型中评估间充质干基质细胞(MSCs)疗效与机制。结果显示SSc-ILD患者CD3+和CD4+ T细胞PD-1表达显著升高,CD4+PD-1+ T细胞随肺纤维化加重而增多并直接刺激成纤维细胞上调胶原与TGF-β1;MSCs经PD-L1依赖机制抑制PD-1+ T细胞,减轻肺部炎症与纤维化。

要点

  • SSc-ILD患者CD3+和CD4+ T细胞PD-1表达显著高于健康对照及SSc-nILD亚组
  • CD4+PD-1+ T细胞直接刺激成纤维细胞上调胶原和TGF-β1表达
  • MSCs通过PD-L1依赖机制抑制PD-1+ T细胞,减轻小鼠肺纤维化

核心结论

  • CD4+PD-1+ T细胞驱动SSc-ILD纤维化,MSCs通过PD-L1介导机制抑制PD-1+ T细胞改善疾病。
  • PD-1可作为治疗靶点,支持MSCs干预SSc-ILD的临床研究。

研究设计与样本

  • 流式细胞术分析30例SSc患者(含SSc-ILD和SSc-nILD亚组)及15例健康对照的T细胞PD-1表达。
  • 建立博来霉素诱导SSc-ILD小鼠模型,静脉输注MSCs并以siPD-L1敲低PD-L1探索机制。
  • 体外共培养实验评估MSCs对CD4+PD-1+ T细胞增殖和凋亡的影响。

主要发现

  • SSc-ILD患者CD3+和CD4+ T细胞PD-1表达显著高于健康对照和SSc-nILD亚组。
  • 博来霉素诱导小鼠肺组织中CD4+PD-1+ T细胞进行性增多,与肺纤维化严重程度相关。
  • CD4+PD-1+ T细胞直接刺激成纤维细胞上调胶原和转化生长因子β1表达。
  • MSCs治疗减少博来霉素诱导小鼠肺部炎症、纤维化及肺组织PD-1+ T细胞频率。
  • MSCs疗效呈PD-L1依赖,由MSC诱导的抑制所介导。

临床怎么用

  • SSc-ILD患者CD4+PD-1+ T细胞升高提示PD-1/PD-L1轴可作为潜在治疗靶点。
  • MSCs经PD-L1依赖机制抑制PD-1+ T细胞,支持其治疗SSc-ILD的临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterised by progressive pulmonary fibrosis. This study aimed to investigate the role of programmed death-1 (PD-1)-expressing T cells in SSc-ILD pathogenesis and evaluate the therapeutic potential and mechanism of mesenchymal stromal cells (MSCs) in mitigating fibrosis. METHODS: PD-1 expression in T cells from 30 patients with SSc (including SSc-ILD and SSc-non-ILD (nILD) subgroups) and 15 healthy controls (HCs) was analysed via flow cytometry. A bleomycin (BLM)-induced SSc-ILD mouse model was established to evaluate the effects of MSCs in the treatment of lung collagen deposition and inflammation in SSc-ILD. MSCs were administered intravenously to BLM-treated mice, with programmed death-ligand 1 (PD-L1) knockdown (using small interfering RNA targeting PD-L1, siPD-L1) used to explore the mechanism of MSCs on PD-1/PD-L1 pathway. The effects of MSCs on CD4+PD-1+ T cell proliferation and apoptosis were evaluated by in vitro co-culture experiment. RESULTS: PD-1 expression was significantly elevated in CD3+ and CD4+ T cells of patients with SSc-ILD compared with HCs and SSc-nILD subgroups. In BLM-induced mice, CD4+PD-1+ T cells in the lung tissues increased progressively, which was correlated with the severity of lung fibrosis. CD4+PD-1+ T cells directly stimulated fibroblasts to upregulate the expression of collagen and transforming growth factor β1. Treatment with MSCs reduced pulmonary inflammation, fibrosis and PD-1+ T cell frequencies in lung tissues of BLM-induced mice. This therapeutic effect was PD-L1-dependent, as it was mediated by the MSC-induced suppression. CONCLUSION: CD4+PD-1+ T cells drive fibrosis in SSc-ILD, and MSCs ameliorate disease by suppressing PD-1+ T cells through PD-L1-mediated mechanisms. These findings highlight PD-1 as a therapeutic target and support the clinical investigation of MSC-based interventions for SSc-ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Chen Y, Zhu H, Zhang Y, et al. Mesenchymal stromal cells ameliorate systemic sclerosis-interstitial lung disease via PD-1/PD-L1 signalling axis. RMD Open. 2026. PMID: 41494735. doi:10.1136/rmdopen-2025-006324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。